CMRA Stock Overview
A preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Comera Life Sciences Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0003 |
| 52 Week High | US$0.13 |
| 52 Week Low | US$0.000001 |
| Beta | -20.43 |
| 11 Month Change | 200.00% |
| 3 Month Change | n/a |
| 1 Year Change | -99.43% |
| 33 Year Change | -100.00% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Comera Life Sciences rises on positive preclinical data from Sequrus study
Oct 18Comera life sciences expands woburn operations
Oct 04Comera Life Sciences announces up to $15M purchase agreement with Arena
Aug 31Comera Life Sciences GAAP EPS of -$1.14, revenue of $0.15M
Aug 10Comera Life Sciences Holdings (NASDAQ:CMRA) Is In A Good Position To Deliver On Growth Plans
May 27
Shareholder Returns
| CMRA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 200.0% | 2.4% | 2.2% |
| 1Y | -99.4% | 16.2% | 31.7% |
Return vs Industry: CMRA underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: CMRA underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| CMRA volatility | |
|---|---|
| CMRA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CMRA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CMRA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 13 | Michael Campbell | comeralifesciences.com |
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company’s lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn’s disease and ulcerative colitis.
Comera Life Sciences Holdings, Inc. Fundamentals Summary
| CMRA fundamental statistics | |
|---|---|
| Market cap | US$9.22k |
| Earnings (TTM) | -US$9.35m |
| Revenue (TTM) | US$1.00m |
0.0x
P/S Ratio0.0x
P/E RatioIs CMRA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CMRA income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | US$264.88k |
| Gross Profit | US$735.52k |
| Other Expenses | US$10.09m |
| Earnings | -US$9.35m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 73.52% |
| Net Profit Margin | -934.95% |
| Debt/Equity Ratio | 381.2% |
How did CMRA perform over the long term?
See historical performance and comparison